|
Citing “unprecedented demand,” drugmaker Novo Nordisk said Thursday it expects supply restrictions on starter doses of the weight loss medicine Wegovy to persist into 2024, several months beyond its previous prediction.
The company is prioritizing higher, or so-called maintenance, doses of the medicine so that patients who have already started taking Wegovy can continue to access the drug, Doug Langa, executive vice president of North America Operations, told CNN. Novo Nordisk had said in May it expected supply restrictions on lower doses to continue through September.
Novo Nordisk expects Wegovy (Semaglutide) starter dose restrictions to persist into 2024, longer than previously forecasted. If you see one of our providers and qualify for Wegovy and do not want to wait or if your BMI is not in the obese range and would not qualify for it to be covered by insurance, we can give you a prescription and refer you to purchase compounded semaglutide from a quality weight loss center.
Schedule a Weight Consultation with either Alicia Loper or Rayna Tarlow.
Read the rest of the article on our website here.
|